Evaluating the impact of tumor microenvironment on treatment outcomes in advanced gastric cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the relationship between the efficacy of perioperative drug treatment and the tumor microenvironment in patients with locally advanced resectable gastric and gastroesophageal junction adenocarcinoma. By analyzing tumor microenvironment scores derived from transcriptomic data, the study seeks to identify potential biomarkers that can predict treatment outcomes and guide personalized immunotherapy strategies. Eligible patients will provide residual tumor tissue samples for analysis, and their treatment will follow established clinical guidelines. The goal is to enhance the understanding of how the tumor microenvironment influences treatment efficacy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histologically or cytologically confirmed locally advanced resectable gastric and gastro-oesophageal junction adenocarcinoma at the stage of cT2-T4aNxM0 (AJCC 8th) without distant metastases and without infiltration of adjacent structures and organs.
2. 18-75 years old.
3. Willing to provide residual tumor tissues after routine clinical diagnosis for tumor microenvironment detection analysis.
4. Patients agree to participate in the study and sign the informed consent.
5. Patients need to receive perioperative drug therapy.
6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.

Exclusion Criteria:

1. Human epidermal growth factor receptor 2 (HER2) is positive, that is, tissue immunohistochemical staining (IHC) (3+) or IHC (2+), and tissue fluorescence in situ hybridization (FISH) is positive.
2. Patients with major cardiovascular and cerebrovascular diseases (such as congestive heart failure, unstable heart colic, atrial fibrillation, stroke, transient ischemic attack, etc.).
3. Allergies or contraindications to common chemotherapy drugs, immunotherapy drugs or the ingredients.
4. Women who are pregnant, breast-feeding.
5. Other conditions the investigator believes that it is not suitable to participate in this study.

Where it's running

• Nanfang Hospital, Southern Medical University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Wangjun Liao, MD, PhD
• Email: nfyyliaowj@163.com
• Phone: 86-20-62787731

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-powered tumor response assessment after preoperative treatment in stomach and gastroesophageal junction cancer

  Researchers are testing whether an AI tool called DeepTRG can reliably measure how much cancer remains in tissue removed after preoperative therapy in stomach and GEJ cancer, without needing a human to correct the AI results.

  Recruiting Hebei Medical University · Shijiazhuang, None Selected · NCT07849608

• HIPEC-primed therapy with serplulimab plus SOX/XELOX for locally advanced gastric cancer

  This study tests a HIPEC-priming approach followed by PD-1 blocker–based chemotherapy to see if it helps people with locally advanced gastric cancer who have not yet spread.

  Recruiting Phase 2 Shanghai Changzheng Hospital · Shanghai · NCT07621484

• Zolbetuximab with chemotherapy for HER2-negative, Claudin 18.2–positive metastatic gastric or gastroesophageal junction adenocarcinoma

  This project will try zolbetuximab together with FOLFOX or XELOX as first-line treatment for adults whose HER2-negative stomach or gastroesophageal junction cancers strongly express Claudin 18.2.

  Recruiting European Institute of Oncology · Milan · NCT07427992

• BL-M07D1 versus chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer

  This trial tests whether BL-M07D1 works better than a doctor's choice of chemotherapy for adults with HER2‑positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma after first‑line anti‑HER2 therapy has failed.

  Recruiting at 2 sites Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Harbin, Heilongjiang and 1 other locations · NCT07152405

• Adding paclitaxel into the abdominal cavity for gastric cancer that has spread to the peritoneum

  This trial will try adding paclitaxel delivered directly into the abdomen to standard IV chemotherapy for people with gastric or gastroesophageal junction cancer that has spread to the lining of the abdominal cavity to see if it slows disease growth and helps them live longer.

  Recruiting at 78 sites Phase 2/3 Eastern Cooperative Oncology Group · Irvine, California and 77 other locations · NCT07001748

• Combination of OBP-301 and Pembrolizumab for Advanced Esophagogastric Cancer

  This study is trying a new treatment combining OBP-301 and pembrolizumab to see if it can help people with advanced esophageal and gastric cancer who haven't responded well to previous immunotherapy.

  Recruiting at 2 sites Phase 2 Weill Medical College of Cornell University · New York, New York and 1 other locations · NCT06340711

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.